|
시장보고서
상품코드
1478704
지질 나노입자 원료 시장 점유율, 규모, 동향, 산업 분석 보고서 : 제품별, 적응 질환별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2032년)Lipid Nanoparticle Raw Materials Market Share, Size, Trends, Industry Analysis Report, By Product (Ionizable lipids, Reagents, Other raw materials); By Disease Indication; By Application; By End-use; By Region; Segment Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 연구에 따르면 지질 나노입자 원료 세계 시장 규모는 2032년까지 3억 3,385만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
지질 나노입자 원료에 대한 수요 증가는 백신 개발에 대한 관심이 높아진 데 크게 기인합니다. 전 세계 인구는 만성 건강 문제, 특히 암과 혈액 관련 질환의 급격한 증가를 목격하고 있습니다. 이에 따라 의료 연구자들은 시장에서 효과적인 진단 및 치료 절차를 개발해야 할 필요성이 대두되고 있으며, 이는 지질 나노입자 원료에 대한 수요를 크게 촉진할 것입니다. 예를 들어, 2023년 10월, 생물 의학 연구소 연구진은 대장염 관련 암에 대한 경구용 액체 나노입자 약물의 개발을 발표했습니다.
새로운 연구기관의 개척이 증가함에 따라 세계 지질 나노입자 원료 시장에 긍정적인 영향을 미치고 있습니다. 예를 들어, 2023년 9월, Centre for Process Innovation은 영국에 Center of Excellence RNA를 설립하여 임상시험용 지질 나노입자와 RNA 생산을 목표로 하고 있습니다. 또한 과학 발전을 촉진하기 위한 정부의 투자 및 보조금 증가는 장기적으로 지질 나노입자의 생산을 더욱 촉진할 것으로 예상되며, 특히 불충분한 백신 문제를 해결하기 위한 것입니다. 예를 들어, 2023년 9월, Centre of Excellence RNA는 RNA 생산 및 개발 활동에서 기업을 지원하기 위해 2,600만 파운드의 자금을 지원받았습니다.
또한, 현재 진행 중인 제품 출시는 백신, 세포 및 유전자 치료제 제조를 위한 지질 나노입자 개발의 진전을 뒷받침하고 있습니다. 예를 들어, 2024년 4월 Cayman Chemicals는 지질 나노입자를 발견할 수 있는 LipidLaunch 연구 도구를 발표했습니다. 연구 혁신이 진행됨에 따라 지질 나노입자의 진정한 잠재력이 밝혀져 조사 기간 동안 시장 성장을 촉진할 가능성이 높습니다. 예를 들어, Nature Communication지에 게재된 2024년 연구는 나노입자를 이용한 표적 폐 운반체 시스템을 개발했습니다.
또한, 지질 나노입자 생산능력을 향상시키기 위해 연구자들이 지질 나노입자 생산능력을 향상시키기 위해 취한 노력의 증가는 지질 나노입자 원료 시장의 성장을 촉진 할 가능성이 높습니다. 예를 들어, 2023년 8월, 연구원들은 지질 나노입자 백신(SARS-CoV-2 mRNA)의 높은 생산 속도를 가능하게 하는 새로운 플랫폼의 출시를 발표했습니다.
지질 나노입자 원료 시장 보고서 하이라이트
키트 부문은 저렴한 가격과 연구 활동의 유연성으로 인해 가장 높은 성장세를 보일 것으로 예상됩니다.
감염병 부문은 감염으로 인한 건강 문제가 증가함에 따라 가장 큰 시장 점유율을 차지합니다.
치료제 부문은 치료법 개발이 진행 중이기 때문에 더 큰 매출 비중을 차지할 것으로 예상됩니다.
아시아태평양은 예측 기간 동안 가장 빠른 성장을 기록할 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 지질 나노입자 원료 시장 인사이트
- 용도 현황
- 지질 나노입자 원료 시장 역학
- 성장 촉진요인과 기회
- 폐적응 질환 발생률 상승
- 다수의 치료 제제의 mRNA 기술 채용 증가
- 성장 억제요인과 과제
- 복잡한 생산 공정이 시장 성장을 저해할 가능성이 있다
- 성장 촉진요인과 기회
- PESTEL 분석
- 지질 나노입자 원료 시장 응용 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 지질 나노입자 원료 시장 : 적응 질환별
- 주요 조사 결과
- 소개
- 암
- 감염증
- 혈액 적응 질환
- 기타
제6장 세계의 지질 나노입자 원료 시장 : 제품별
- 주요 조사 결과
- 소개
- 키트
- 시약
- 기타
제7장 세계의 지질 나노입자 원료 시장 : 용도별
- 주요 조사 결과
- 소개
- 치료
- 연구
제8장 세계의 지질 나노입자 원료 시장 : 지역별
- 주요 조사 결과
- 소개
- 지질 나노입자 원료 시장 평가 : 지역별, 2019-2032년
- 북미
- 북미 : 적응 질환별, 2019-2032년
- 북미 : 용도별, 2019-2032년
- 북미 : 제품별, 2019-2032년
- 미국
- 캐나다
- 유럽
- 유럽 : 적응 질환별, 2019-2032년
- 유럽 : 용도별, 2019-2032년
- 유럽 : 제품별, 2019-2032년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 아시아태평양
- 아시아태평양 : 적응 질환별, 2019-2032년
- 아시아태평양 : 용도별, 2019-2032년
- 아시아태평양 : 제품별, 2019-2032년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 중동 및 아프리카
- 중동 및 아프리카 : 질병별, 2019-2032년
- 중동 및 아프리카 : 용도별, 2019-2032년
- 중동 및 아프리카 : 제품별, 2019-2032년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 라틴아메리카
- 라틴아메리카 : 질병별, 2019-2032년
- 라틴아메리카 : 용도별, 2019-2032년
- 라틴아메리카 : 제품별, 2019-2032년
- 멕시코
- 브라질
- 아르헨티나
제9장 경쟁 상황
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Avanti Polar Lipids(미국)
- .Biopharma PEG Scientific Inc.(미국)
- BroadPharm(미국)
- CordenPharma International(독일)
- Creative Biolabs(미국)
- Echelon Biosciences(미국)
- Merck KGaA(독일)
- NOF AMERICA CORPORATION(미국)
- Polysciences, Inc.(미국)
- Tebu Bio(프랑스)
The global lipid nanoparticle raw materials market size is expected to reach USD 333.85 million by 2032, according to a new study by Polaris Market Research. The report "Lipid Nanoparticle Raw Materials Market Share, Size, Trends, Industry Analysis Report, By Product (Ionizable lipids, Reagents, Other raw materials); By Disease Indication; By Application; By End-use; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising demand for the lipid nanoparticle raw materials is highly attributable to the increasing focus on vaccination development. The worldwide population is witnessing a significant surge in chronic health issues, specifically cancer and blood diseases. This is enforcing healthcare researchers to formulate effective diagnosis and treatment procedures in the marketplace, which will significantly facilitate the need for lipid nanoparticle raw materials. For instance, in October 2023, the researchers at the Institute for Biomedical Science announced the development of an oral liquid nanoparticle drug for colitis-associated cancer.
The increasing development of new research institutes is optimally influencing the global lipid nanoparticle raw material market. For instance, in September 2023, Centre for Process Innovation introduced the Center of Excellence RNA in the UK, aiming to produce lipid nanoparticles and RNA for clinical trials. Additionally, the rising investments and grants by the government to fuel scientific developments, specifically to address the problem of inadequate vaccines, will further fuel the production of lipid nanoparticles in the long run. For instance, in September 2023, the RNA Centre of Excellence received funding of GBP 26 million to assist companies in the production and development activities of RNA.
Furthermore, the ongoing product launches are supporting advancements in the development of lipid nanoparticles for the manufacturing of vaccines, cell and gene therapies. For instance, in April 2024, Cayman Chemicals introduced the LipidLaunch research tools that have the potential to discover lipid nanoparticles. The growing research innovations unravel the true potential of the lipid nanoparticles, which will likely drive market growth during the study period. For instance, a 2024 study published in Nature Communication developed the targeted lung carrier system with the use of nanoparticles.
Additionally, the rising efforts taken by the researchers to increase the production capacity of lipid nanoparticles are likely to drive the growth of the lipid nanoparticle raw material market. For instance, in August 2023, researchers unveiled the launch of a new platform that enables a higher rate of production of lipid nanoparticle vaccines (SARS-CoV-2 mRNA).
Lipid Nanoparticle Raw Materials Market Report Highlights
Kits segment is anticipated to witness the highest growth due to its affordability and flexibility in research activities.
Infectious disease segment accounted for the largest market share owing to the increasing number of health issues due to infections.
Therapeutics segment is projected to experience a larger revenue share due to the growing development of therapies.
APAC is projected to register the fastest growth during the forecast period, attributable to the increasing blood cancer rate in the region.
The global players include Avanti Polar Lipids, Biopharma PEG Scientific Inc., BroadPharm, CordenPharma International, Creative Biolabs, & Echelon Biosciences.
Polaris Market Research has segmented the lipid nanoparticle raw materials market report based on product, disease indication, application, end-use, and region:
Lipid Nanoparticle Raw Materials, Product Outlook (Revenue - USD Million, 2019 - 2032)
- Ionizable lipids
- PEGylated lipids
- Sterol lipids
- Neutral phospholipids
- Kits
- Reagents
- Other raw materials
Lipid Nanoparticle Raw Materials, Disease Indication Outlook (Revenue - USD Million, 2019 - 2032)
- Cancer
- Infectious Diseases
- Blood Diseases
- Others
Lipid Nanoparticle Raw Materials, Application Outlook (Revenue - USD Million, 2019 - 2032)
- Therapeutics
- Research
Lipid Nanoparticle Raw Materials, End-use Outlook (Revenue - USD Million, 2019 - 2032)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
Lipid Nanoparticle Raw Materials, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Lipid Nanoparticle Raw Materials Market Insights
- 4.1. Lipid Nanoparticle Raw Materials Market - Application Snapshot
- 4.2. Lipid Nanoparticle Raw Materials Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising incidence of lung diseases
- 4.2.1.2. Increasing adoption of mRNA technology in multiple therapeutic formulations
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Complex production process is likely to impede market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Lipid Nanoparticle Raw Materials Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Lipid Nanoparticle Raw Materials Market, by Disease Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 5.3. Cancer
- 5.3.1. Global Lipid Nanoparticle Raw Materials Market, by Cancer, by Region, 2019-2032 (USD Million)
- 5.4. Infectious Diseases
- 5.4.1. Global Lipid Nanoparticle Raw Materials Market, by Infectious Diseases, by Region, 2019-2032 (USD Million)
- 5.5. Blood Diseases
- 5.5.1. Global Lipid Nanoparticle Raw Materials Market, by Blood Diseases, by Region, 2019-2032 (USD Million)
- 5.6. Others
- 5.6.1. Global Lipid Nanoparticle Raw Materials Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Lipid Nanoparticle Raw Materials Market, by Product
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 6.3. Ionizable lipids
- 6.3.1. Global Lipid Nanoparticle Raw Materials Market, by Ionizable lipids, by Region, 2019-2032 (USD Million)
- 6.4. Reagents
- 6.4.1. Global Lipid Nanoparticle Raw Materials Market, by Reagents, by Region, 2019-2032 (USD Million)
- 6.5. Other raw materials
- 6.5.1. Global Lipid Nanoparticle Raw Materials Market, by Other raw materials, by Region, 2019-2032 (USD Million)
7. Global Lipid Nanoparticle Raw Materials Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 7.3. Therapeutics
- 7.3.1. Global Lipid Nanoparticle Raw Materials Market, by Therapeutics, By Region, 2019-2032 (USD Million)
- 7.4. Research
- 7.4.1. Global Lipid Nanoparticle Raw Materials Market, by Research, By Region, 2019-2032 (USD Million)
8. Global Lipid Nanoparticle Raw Materials Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Lipid Nanoparticle Raw Materials Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Lipid Nanoparticle Raw Materials Market - North America
- 8.3.1. North America: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.3.2. North America: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.3.3. North America: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.3.4. Lipid Nanoparticle Raw Materials Market - U.S.
- 8.3.4.1. U.S.: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.3.5. Lipid Nanoparticle Raw Materials Market - Canada
- 8.3.5.1. Canada: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.3.5.3. Canada: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4. Lipid Nanoparticle Raw Materials Market - Europe
- 8.4.1. Europe: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.2. Europe.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.3. Europe: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.4. Lipid Nanoparticle Raw Materials Market - UK
- 8.4.4.1. UK: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.4.3. UK: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.5. Lipid Nanoparticle Raw Materials Market - France
- 8.4.5.1. France: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.5.2. France.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.5.3. France: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.6. Lipid Nanoparticle Raw Materials Market - Germany
- 8.4.6.1. Germany: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.6.3. Germany: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.7. Lipid Nanoparticle Raw Materials Market - Italy
- 8.4.7.1. Italy: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.7.3. Italy: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.8. Lipid Nanoparticle Raw Materials Market - Spain
- 8.4.8.1. Spain: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.8.3. Spain: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.9. Lipid Nanoparticle Raw Materials Market - Netherlands
- 8.4.9.1. Netherlands: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.4.10. Lipid Nanoparticle Raw Materials Market - Russia
- 8.4.10.1. Russia: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.4.10.3. Russia: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5. Lipid Nanoparticle Raw Materials Market - Asia Pacific
- 8.5.1. Asia Pacific: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.4. Lipid Nanoparticle Raw Materials Market - China
- 8.5.4.1. China: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.4.2. China.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.4.3. China: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.5. Lipid Nanoparticle Raw Materials Market - India
- 8.5.5.1. India: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.5.2. India.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.5.3. India: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.6. Lipid Nanoparticle Raw Materials Market - Malaysia
- 8.5.6.1. Malaysia: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.7. Lipid Nanoparticle Raw Materials Market - Japan
- 8.5.7.1. Japan: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.7.3. Japan: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.8. Lipid Nanoparticle Raw Materials Market - Indonesia
- 8.5.8.1. Indonesia: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.5.9. Lipid Nanoparticle Raw Materials Market - South Korea
- 8.5.9.1. South Korea: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.6. Lipid Nanoparticle Raw Materials Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.6.4. Lipid Nanoparticle Raw Materials Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.6.5. Lipid Nanoparticle Raw Materials Market - UAE
- 8.6.5.1. UAE: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.6.5.3. UAE: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.6.6. Lipid Nanoparticle Raw Materials Market - Israel
- 8.6.6.1. Israel: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.6.6.3. Israel: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.6.7. Lipid Nanoparticle Raw Materials Market - South Africa
- 8.6.7.1. South Africa: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.7. Lipid Nanoparticle Raw Materials Market - Latin America
- 8.7.1. Latin America: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.7.3. Latin America: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.7.4. Lipid Nanoparticle Raw Materials Market - Mexico
- 8.7.4.1. Mexico: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.7.5. Lipid Nanoparticle Raw Materials Market - Brazil
- 8.7.5.1. Brazil: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
- 8.7.6. Lipid Nanoparticle Raw Materials Market - Argentina
- 8.7.6.1. Argentina: Lipid Nanoparticle Raw Materials Market, by Disease Indication, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Lipid Nanoparticle Raw Materials Market, by Application , 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Lipid Nanoparticle Raw Materials Market, by Product, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Avanti Polar Lipids (US)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. .Biopharma PEG Scientific Inc. (US)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. BroadPharm (US)
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. CordenPharma International (Germany)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Creative Biolabs (US)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Echelon Biosciences (US)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Merck KGaA (Germany)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. NOF AMERICA CORPORATION (US)
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Polysciences, Inc. (US)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Tebu Bio (France)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
